<\/p>\n
Warf<\/strong> is 1 \/ 2 \/ 5 mg warfarin tablets from a WHO-GMP certified manufacturer — an oral vitamin K antagonist (VKA) anticoagulant. Warfarin was first synthesised from dicoumarol in the 1940s and approved as a human drug in 1954; despite the rise of DOACs it remains first-line for mechanical heart valves, moderate-to-severe mitral stenosis, and antiphospholipid syndrome. Mechanism: blocks vitamin K epoxide reductase (VKORC1), depleting the active forms of clotting factors II, VII, IX, X plus proteins C and S. Onset is delayed 3-5 days because circulating factors must decay. Dose is highly individualised and INR-driven — target INR 2.0-3.0 in most indications, 2.5-3.5 for mechanical mitral or older aortic prostheses. Daily intake of vitamin K (greens) should be consistent rather than avoided. Major bleeding rate ~1-3%\/year on therapeutic warfarin. Reversal: oral or IV vitamin K plus 4-factor prothrombin complex concentrate for major bleeding. Specialist or family-physician supervision is standard.<\/p>\n<\/div>\n \ud83d\udce6 Varje best\u00e4llning omfattas av v\u00e5r Reshipment Assurance Policy<\/strong><\/a> \u2014 om din f\u00f6rs\u00e4ndelse inte anl\u00e4nder inom 20 arbetsdagar, skickar vi om den.<\/p>\n V\u00e5ra generiska l\u00e4kemedel kommer fr\u00e5n WHO-GMP-certifierade tillverkare och skickas v\u00e4rldsvidt i diskreta, enkla f\u00f6rpackningar \u2014 inget l\u00e4kemedelsnamn p\u00e5 f\u00f6rs\u00e4ndelsens utsida. Kortbetalningar hanteras via en reglerad betalningsprocessor (kontoutdrag visar en reglerad kortbetalningsprocessor \u2014 aldrig \u201cMedsBase\u201d eller n\u00e5got l\u00e4kemedelsnamn). Krypto och SEPA-bank\u00f6verf\u00f6ring accepteras ocks\u00e5. Varje best\u00e4llning backas upp av v\u00e5r Reshipment Assurance Policy.<\/p>\n Warf is 1 \/ 2 \/ 5 mg warfarin sodium tablets from a WHO-GMP certified manufacturer, supplied in 30-180 tablets. Warfarin is the most widely used oral anticoagulant in the world. Despite the introduction of direct oral anticoagulants (DOACs), warfarin remains the first-line choice in mechanical heart valves, rheumatic mitral stenosis, antiphospholipid syndrome, and selected high-risk patients where DOAC evidence is weak.<\/p>\n Warfarin h\u00e4mmar vitamin K-epoxidreduktas (VKORC1) i hepatocyter, vilket blockerar \u00e5tervinningen av vitamin K. Detta minskar de aktiva \u03b3-karboxylerade formerna av faktor II, VII, IX och X samt de naturliga antikoagulantia protein C och S. Den antikoagulerande effekten uppskjuts med 3-5 dagar eftersom befintliga cirkulerande faktorer kataboliseras \u2014 \u00f6verg\u00e5ng med parenteral heparin eller LMWH kr\u00e4vs n\u00e4r snabb antikoagulering beh\u00f6vs.<\/p>\n Warfarindos \u00e4r mycket individuell och titreras efter den internationella normaliserade kvoten (INR). Typisk underh\u00e5llsdos \u00e4r 2\u201310 mg dagligen men kan variera fr\u00e5n 15 mg.<\/p>\nVarf\u00f6r best\u00e4lla fr\u00e5n MedsBase<\/h3>\n
What Is Warf?<\/h2>\n
Hur Warfarin fungerar<\/h2>\n
Godk\u00e4nda Anv\u00e4ndningsomr\u00e5den<\/h2>\n
\n
Dosering och INR-m\u00e5l<\/h2>\n